ACXP Earnings Prediction
The chart below shows how ACXP performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ACXP sees a +17.27% change in stock price 10 days leading up to the earnings, and a +5.64% change 10 days following the report. On the earnings day itself, the stock moves by -4.01%. This data can give you a slight idea of what to expect for the next quarter's release.
ACXP Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
-0.17
-29.17%
-34.62%
No Data Available
ACXP Earnings Analysis
Acurx Pharmaceuticals, Inc. Common Stock Corporation (ACXP.O) Earnings Conference Call
Positive
Phase II Trial Results: 1. Successful Phase II Clinical Trial Presentation: Results from the ibezapolstat Phase II clinical trial in patients with C. diff infection were presented, showcasing its clinical efficacy and potential as a treatment option.
Patent Approval for Ibezapolstat: 2. New Patent Granted: Acurx received a new patent for ibezapolstat, which encompasses the treatment of C. difficile infection, providing a competitive advantage with an expiration date in June 2042.
Cash Balance Increase: 3. Cash Position Improvement: The company raised approximately $1.6 million in gross proceeds under its ATM financing program during the third quarter, contributing to a cash balance of $5.8 million.
Reduced Net Loss: 4. Decreased Net Loss: The net loss for the third quarter was reduced to $2.8 million, or $0.17 per diluted share, compared to a net loss of $3.1 million, or $0.24 per diluted share, in the same quarter last year.
Clinical Trial Success: 5. Positive Clinical Outcomes: In the Phase IIb clinical trial, ibezapolstat demonstrated comparable clinical cure and sustained cure rates to vancomycin, with no recurrence in 505 patients followed for three months post-treatment.
Negative
Cash Reserves Decline: 1. Declining Cash Reserves: Acurx ended Q3 2024 with cash totaling $5.8 million, down from $7.5 million at the end of 2023.
Net Loss Comparison: 2. Increased Net Loss: The company reported a net loss of $2.8 million for Q3 2024, compared to a net loss of $3.1 million in Q3 2023, indicating ongoing financial challenges.
R&D Expense Rise: 3. R&D Expense Increase: Research and development expenses rose to $4.6 million for the first nine months of 2024, up from $4.1 million in the same period of 2023, primarily due to increased manufacturing costs.
Administrative Expense Increase: 4. General and Administrative Expense Growth: General and administrative expenses increased to $6.7 million for the first nine months of 2024, compared to $5.4 million in the same period of 2023, reflecting rising professional and legal costs.
Non-Dilutive Funding Strategies: 5. Shareholder Dilution Concerns: The company is exploring non-dilutive funding options for its Phase III trials, indicating potential challenges in securing necessary capital without affecting shareholder equity.
ACXP FAQs
How does ACXP typically perform around its earnings report dates?
Is Acurx Pharmaceuticals, Inc. (ACXP) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
ACXP Earning Call Sentiment
Acurx Pharmaceuticals, Inc. (ACXP) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
ACXP.O
0%Positive
The earnings call summary highlighted several concerns: financial risks with a reported net loss, supply chain challenges, and competitive pressures in the antibiotic market. The Q&A section revealed uncertainties in regulatory filings and unclear timelines for Phase III trials. Despite potential partnerships and non-dilutive funding options, the lack of clear guidance and ongoing financial challenges suggest a negative sentiment. The ATM financing program and additional proceeds are insufficient to offset these concerns, leading to a predicted stock price movement in the negative range (-2% to -8%) over the next two weeks.
